UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Promising treatment modalities in the therapy of myelodysplastic syndromes

Klinická onkologie, 2021-10, Vol.34 (5)

Jonášová, Anna

2021

Volltextzugriff (PDF)

Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow

British journal of haematology, 1998-02, Vol.100 (2), p.304-309

1998

Volltextzugriff (PDF)

Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis

British journal of haematology, 2024-07

2024

Volltextzugriff (PDF)

G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial

Blood cancer journal (New York), 2022-07, Vol.12 (7), p.105-105, Article 105

2022

Volltextzugriff (PDF)

Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways

Cells (Basel, Switzerland), 2022-01, Vol.11 (2), p.223

2022

Volltextzugriff (PDF)

Characterization and Management of Cytopenias after Imetelstat Treatment in the IMerge Phase 3 Trial of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Blood, 2023-11, Vol.142 (Supplement 1), p.6478-6478

2023

Volltextzugriff (PDF)

Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of combination with erythropoietin alfa

Frontiers in oncology, 2024-10, Vol.14, p.1398331

2024

Volltextzugriff (PDF)

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2024-01, Vol.403 (10423), p.249-260

2024

Volltextzugriff (PDF)

Epigenetic control of SPI1 gene by CTCF and ISWI ATPase SMARCA5

PloS one, 2014-02, Vol.9 (2), p.e87448

2014

Volltextzugriff (PDF)

Expression of circular RNAs in myelodysplastic neoplasms and their association with mutations in the splicing factor gene SF3B1

Molecular oncology, 2023-12, Vol.17 (12), p.2565-2583

2023

Volltextzugriff (PDF)

Effect of erythropoietin on hepcidin expression in hemojuvelin-mutant mice

Blood cells, molecules, & diseases, 2010-04, Vol.44 (4), p.257-261

2010

Volltextzugriff (PDF)

Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes

Molecular oncology, 2020-10, Vol.14 (10), p.2403-2419

2020

Volltextzugriff (PDF)

Overall Survival (OS), Clinical Benefit, and Durable Red Blood Cell (RBC) Transfusion Independence (TI) With Imetelstat in the IMerge Phase 3 Trial of RBC-Transfusion Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S192-S192

2024

Volltextzugriff (PDF)

Overall Survival (OS), Clinical Benefit, and Durable Red Blood Cell (RBC) Transfusion Independence (TI) With Imetelstat in the IMerge Phase 3 Trial of RBC-Transfusion Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S153-S153

2024

Volltextzugriff (PDF)

MDS-157 Overall Survival (OS), Clinical Benefit, and Durable Red Blood Cell (RBC) Transfusion Independence (TI) With Imetelstat in the IMerge Phase 3 Trial of RBC-Transfusion Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S386-S387

2024

Volltextzugriff (PDF)

Verification of Survival Predictors in Elderly Patients with Myelodysplastic Syndrome from Outpatient Clinical Practice

International journal of gerontology, 2018-03, Vol.12 (1), p.27-31

2018

Volltextzugriff (PDF)

Improved hematopoietic stem cell transplantation upon inhibition of natural killer cell-derived interferon-gamma

Stem cell reports, 2021-08, Vol.16 (8), p.1999-2013

2021

Volltextzugriff (PDF)

Circulating Small Noncoding RNAs Have Specific Expression Patterns in Plasma and Extracellular Vesicles in Myelodysplastic Syndromes and Are Predictive of Patient Outcome

Cells (Basel, Switzerland), 2020-03, Vol.9 (4), p.794

2020

Volltextzugriff (PDF)

1 – 25 von 145

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(140)
Mit Volltextzugriff
(142)

Publikationsform

Artikel
(143)
Berichte
(2)

Sprache

Englisch
(144)
Tschechisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(60)
Life Sciences & Biomedicine
(58)
Humans
(39)
Hematology
(36)
Oncology
(35)
Female
(27)
Male
(27)
Aged
(24)
Middle Aged
(24)
Myelodysplastic Syndromes
(24)
Myelodysplastic Syndrome
(21)
Myelodysplastic Syndromes - Genetics
(21)
Adult
(20)
Aged, 80 And Over
(18)
Myelodysplastic Syndromes - Drug Therapy
(15)
Acute Myeloid Leukemia
(13)
Prognosis
(13)
Chromosome Deletion
(11)
Hematology, Oncology And Palliative Medicine
(10)
Patients
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY

Promising treatment modalities in the therapy of myelodysplastic syndromes

P732: ANALYSIS OF PATIENT‐REPORTED FATIGUE IN IMERGE PH3 TRIAL OF IMETELSTAT VS PLACEBO IN HEAVILY TRANSFUSED NON‐DEL(5Q) LOWER‐RISK MYELODYSPLASTIC SYNDROMES R/R TO ERYTHROPOIESIS STIMULATING AGENTS

S165: CONTINUOUS TRANFUSION INDEPENDENCE WITH IMETELSTAT IN HEAVILY TRANSFUSED NON‐DEL(5Q) LOWER‐RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3

S164: DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON‐DEL(5Q) LOWER‐RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3

Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow

Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis

G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial

Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways

Characterization and Management of Cytopenias after Imetelstat Treatment in the IMerge Phase 3 Trial of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of combination with erythropoietin alfa

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

Durable Continuous Transfusion Independence (TI) with Imetelstat in IMerge Phase 3 for Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to or Ineligible for Erythropoiesis-Stimulating Agents (ESAs)

Epigenetic control of SPI1 gene by CTCF and ISWI ATPase SMARCA5

Expression of circular RNAs in myelodysplastic neoplasms and their association with mutations in the splicing factor gene SF3B1

Effect of erythropoietin on hepcidin expression in hemojuvelin-mutant mice

Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes

Overall Survival (OS), Clinical Benefit, and Durable Red Blood Cell (RBC) Transfusion Independence (TI) With Imetelstat in the IMerge Phase 3 Trial of RBC-Transfusion Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Overall Survival (OS), Clinical Benefit, and Durable Red Blood Cell (RBC) Transfusion Independence (TI) With Imetelstat in the IMerge Phase 3 Trial of RBC-Transfusion Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)

MDS-157 Overall Survival (OS), Clinical Benefit, and Durable Red Blood Cell (RBC) Transfusion Independence (TI) With Imetelstat in the IMerge Phase 3 Trial of RBC-Transfusion Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Verification of Survival Predictors in Elderly Patients with Myelodysplastic Syndrome from Outpatient Clinical Practice

Improved hematopoietic stem cell transplantation upon inhibition of natural killer cell-derived interferon-gamma

Circulating Small Noncoding RNAs Have Specific Expression Patterns in Plasma and Extracellular Vesicles in Myelodysplastic Syndromes and Are Predictive of Patient Outcome

POSTER: MDS-157 Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Requiring Red Blood Cell (RBC) Transfusions: Data from the Phase III COMMANDS Study

Oral Abstract: MDS-157 Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Requiring Red Blood Cell (RBC) Transfusions: Data from the Phase III COMMANDS Study

Suchergebnisse filtern